ReviewFrontiers in oncology2026
Natural product derived phytochemicals as modulators of cancer stemness and drug resistance.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural secondary metabolites, especially Essential oils (EOs), are compounds made by aromatic plants. These oils contain a variety of bioactive molecules with distinct effects on the body and are known for their strong, low toxicity and wide-ranging biological activities. These herbal concentrates have antimicrobial, antioxidant, anti-inflammatory, antiproliferative, and anticancer effects, mainly due to their terpene and phenolic compounds. Research shows that volatile oils can target cancer cells and may boost the effectiveness of conventional chemotherapy. Using plant based compounds to target drug resistant cancer stem cells (CSCs) is a newer strategy in cancer prevention and treatment. Even though we know more about how cells turn cancerous, cancer is still a major global health issue. This is mostly because cancer cells can resist many different standard drugs. Tumours turn resistant due to their ability to adapt and their frequent exposure to anti-cancer drugs. This review summarises current preclinical evidence on the potential of EOs to modulate CSC associated signalling pathways and overcome CSC mediated drug resistance. It highlights the multitarget mechanisms by which EOs influence CSC maintenance, self-renewal and therapeutic resistance, whilst critically acknowledging that the available evidence is largely limited to preclinical studies. It also emphasises the need for standardised EO characterisation, detailed mechanistic investigations, advanced drug delivery systems to improve bioavailability and pharmacokinetics and well-designed clinical studies to establish the safety, efficacy and therapeutic value of EOs in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.